{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:15:29Z","timestamp":1790162129090,"version":"4.1.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"1212","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Diastolic dysfunction is an important early indicator of heart failure (HF) with preserved ejection fraction (HFpEF). Type 2 diabetes mellitus (T2DM) may contribute to HFpEF, as it is associated with an increased risk of hospitalization and mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To investigate the association between diastolic dysfunction and T2DM in an adult population from Liverpool, accounting for age and sex.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective review of 493 patient records was conducted, extracting data on diastolic function status, diabetes status, age, and sex. Echocardiographic parameters were used to assess and grade diastolic function according to the 2016 ASE\/EACVI recommendations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Diastolic dysfunction was more prevalent in type 2 diabetics (71.42%) than non-diabetic patients (43.98%) (P\u2009&amp;lt;\u2009.05). The odds ratio of developing diastolic dysfunction was 2.636 times higher in diabetics, with 2.56 times greater odds of a higher dysfunction grade (P\u2009&amp;lt;\u2009.001). Age \u226565\u00a0years was associated with 4.65 times higher odds of having diastolic dysfunction, with no significant difference between genders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This retrospective cohort study demonstrates a clear and statistically significant association between T2DM, advancing age and diastolic dysfunction. This association, however, should be interpreted within the context of a clinically selected population undergoing echocardiography. Due to the metabolic alterations that are associated with diabetes and the pathophysiology of HFpEF, there is a great potential for the use antidiabetic therapies as cardioprotective agents aimed at reducing HF morbidity and mortality. Considering these results, we propose incorporating diabetes into the H2FpEF score.<\/jats:p>\n                    <jats:p>Key messages What is already known on this topic \u2013 the development of heart failure with preserved ejection fraction (HFpEF) has long been associated with type 2 diabetes mellitus (T2DM), with the recognition of diastolic dysfunction as an early marker of disease progression. However, data describing the relationship between diabetes and diastolic dysfunction in specific local populations remains limited. What this study adds \u2013 this study provides data from a Liverpool tertiary centre showcasing significantly higher prevalence and severity of diastolic dysfunction in patients with type 2 diabetes. These findings produce locally relevant epidemiological evidence that supports the association between diabetes and diastolic dysfunction. How this study might affect research, practice or policy \u2013 the findings of this study highlight the importance of cardiovascular assessment in patients with type 2 diabetes in certain populations with a high burden of diabetes, such as Liverpool, and may support earlier identification of individuals at risk of developing HFpEF. Future research might consider incorporating T2DM into the H\u2082FPEF score, to improve early risk stratification.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/postmj\/qgag079","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T11:42:34Z","timestamp":1780573354000},"page":"935-941","source":"Crossref","is-referenced-by-count":0,"title":["Diastolic dysfunction and diabetes: the DIADAD study\u2014a retrospective cohort study from Liverpool"],"prefix":"10.1093","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-4723-4132","authenticated-orcid":false,"given":"Laila","family":"Wali","sequence":"first","affiliation":[{"name":"Department of Cardiology, Royal Liverpool University Hospital , Mount Vernon St, Liverpool L7 8YE ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1428-8197","authenticated-orcid":false,"given":"Mohammad Adeeb","family":"Abbara","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Royal Liverpool University Hospital , Mount Vernon St, Liverpool L7 8YE ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sowmya","family":"Ekhelikar","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Royal Liverpool University Hospital , Mount Vernon St, Liverpool L7 8YE ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7475-228X","authenticated-orcid":false,"given":"Jennifer","family":"Pilling","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Royal Liverpool University Hospital , Mount Vernon St, Liverpool L7 8YE ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Albouaini","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Royal Liverpool University Hospital , Mount Vernon St, Liverpool L7 8YE ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott W","family":"Murray","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Royal Liverpool University Hospital , Mount Vernon St, Liverpool L7 8YE ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"2026092306475330100_ref1","volume-title":"IDF DIABETES ATLAS [Internet]","author":"Magliano","year":"2021","edition":"10th"},{"key":"2026092306475330100_ref2","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026092306475330100_ref3","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/0002-9343(83)90403-5","article-title":"Congestive heart failure: echocardiographic insights","volume":"75","author":"Echeverria","year":"1983","journal-title":"Am J Med"},{"key":"2026092306475330100_ref4","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"37","author":"Ponikowski","year":"2020","journal-title":"Eur Heart J"},{"key":"2026092306475330100_ref5","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","article-title":"Diabetic cardiomyopathy","volume":"122","author":"Jia","year":"2018","journal-title":"Circ Res"},{"key":"2026092306475330100_ref6","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1042\/CS20070166","article-title":"Molecular mechanisms for myocardial mitochondrial dysfunction in the metabolic syndrome","volume":"114","author":"Bugger","year":"2008","journal-title":"Clin Sci"},{"key":"2026092306475330100_ref7","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.jacc.2017.11.019","article-title":"Implications of underlying mechanisms for the recognition and management of diabetic cardiomyopathy","volume":"71","author":"Marwick","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026092306475330100_ref8","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1016\/j.jacc.2018.09.042","article-title":"Coronary microvascular disease pathogenic mechanisms and therapeutic options: JACC state-of-the-art review","volume":"72","author":"Taqueti","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026092306475330100_ref9","volume-title":"Diabetes Profile: Statistical Commentary","author":"Office for Health Improvement & Disparities","year":"2025"},{"key":"2026092306475330100_ref10","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.amjcard.2003.12.026","article-title":"Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus","volume":"93","author":"Boyer","year":"2004","journal-title":"Am J Cardiol"},{"key":"2026092306475330100_ref11","first-page":"184","article-title":"Left ventricular function in patients with uncomplicated well-controlled diabetes mellitus","volume":"12","author":"Poant\u0103","year":"2010","journal-title":"Med Ultrason"},{"key":"2026092306475330100_ref12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1161\/CIRCULATIONAHA.107.728550","article-title":"Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension","volume":"117","author":"Van Heerebeek","year":"2008","journal-title":"Circulation"},{"key":"2026092306475330100_ref13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3389\/fendo.2022.983713","article-title":"Profile of crosstalk between glucose and lipid metabolic disturbance and diabetic cardiomyopathy: inflammation and oxidative stress","volume":"13","author":"Chen","year":"2022","journal-title":"Front Endocrinol"},{"key":"2026092306475330100_ref14","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2026092306475330100_ref15","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2026092306475330100_ref16","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"2026092306475330100_ref17","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Michael Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2026092306475330100_ref18","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2024","journal-title":"N Engl J Med"},{"key":"2026092306475330100_ref19","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2026092306475330100_ref20","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026092306475330100_ref21","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"2026092306475330100_ref22","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","article-title":"Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME\u00aetrial","volume":"37","author":"Fitchett","year":"2016","journal-title":"Eur Heart J"},{"key":"2026092306475330100_ref23","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026092306475330100_ref24","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"key":"2026092306475330100_ref25","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"2026092306475330100_ref26","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/ejhf.218","article-title":"Rationale and design of MinerAlocorticoid receptor antagonist tolerability study-heart failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and\/or chronic kidney disease","volume":"17","author":"Pitt","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026092306475330100_ref27","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"2026092306475330100_ref28","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2020","journal-title":"Eur Heart J"},{"key":"2026092306475330100_ref29","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s12933-024-02358-0","article-title":"Prevalence and incidence of heart failure in type 2 diabetes patients: results from a nationwide prospective cohort\u2014the DIABET-IC study","volume":"23","author":"Gonzalez-Manzanares","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"2026092306475330100_ref30","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2023.03.393","article-title":"2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/102\/1212\/935\/68607628\/qgag079.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/102\/1212\/935\/68607628\/qgag079.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T10:48:03Z","timestamp":1790160483000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/article\/102\/1212\/935\/8715752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":30,"journal-issue":{"issue":"1212","published-online":{"date-parts":[[2026,6,24]]},"published-print":{"date-parts":[[2026,9,23]]}},"URL":"https:\/\/doi.org\/10.1093\/postmj\/qgag079","relation":{},"ISSN":["0032-5473","1469-0756"],"issn-type":[{"value":"0032-5473","type":"print"},{"value":"1469-0756","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,6,24]]}}}